FDA Pushes Review Date For Ascendis Pharmas Hormone Disorder Candidate By Three Months

ASND Stock  USD 136.08  0.24  0.18%   
About 56% of Ascendis Pharma's investor base is looking to short. The analysis of the overall investor sentiment regarding Ascendis Pharma AS suggests that many traders are alarmed. The current market sentiment, together with Ascendis Pharma's historical and current headlines, can help investors time the market. In addition, many technical investors use Ascendis Pharma AS stock news signals to limit their universe of possible portfolio assets.
  
Tuesday, Ascendis Pharma AS announced that the FDA extended the review date for TransCon PTH for adults with hypoparathyroidism. Hypoparathyroidism is an uncommon condition in which the body produces abnormally low levels of parathyroid hormone . The low production of PTH in hypoparathyroidism leads to abnormally low calcium levels in the blood and an increase of phosphorus in the blood. The agency said the information Ascendis Pharma submitted in respon

Read at finance.yahoo.com
Yahoo News
  

Ascendis Pharma AS Current Investor Sentiment

Panic Vs Confidence

44

 
Panic
 
Confidence
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use Ascendis Pharma's input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward Ascendis Pharma AS.

Ascendis Pharma Investor Sentiment by Other News Outlets

Investor sentiment, mood or attitude towards Ascendis Pharma can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Ascendis Pharma AS Historical Investor Sentiment

Investor biases related to Ascendis Pharma's public news can be used to forecast risks associated with an investment in Ascendis. The trend in average sentiment can be used to explain how an investor holding Ascendis can time the market purely based on public headlines and social activities around Ascendis Pharma AS. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Ascendis Pharma's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Ascendis Pharma and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Ascendis Pharma news discussions. The higher the estimate score, the more favorable the investor's outlook on Ascendis Pharma.

Ascendis Pharma Fundamental Analysis

We analyze Ascendis Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Ascendis Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Ascendis Pharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Net Asset

Net Asset Comparative Analysis

Ascendis Pharma is currently under evaluation in net asset category among its peers. Net Asset is the current market value of a fund less its liabilities. In a nutshell, if the fund is liquidated or all of the assets is sold out, the net asset will be the amount that the shareholders would demand back from the fund.

Ascendis Pharma AS Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Ascendis Pharma stock to make a market-neutral strategy. Peer analysis of Ascendis Pharma could also be used in its relative valuation, which is a method of valuing Ascendis Pharma by comparing valuation metrics with similar companies.

Peers

Ascendis Pharma Related Equities

BGNEBeiGene   4.29   
0%
100.0%
PLRXPliant Therapeutics   2.00   
0%
46.0%
STOKStoke Therapeutics   1.68   
0%
39.0%
DAWNDay One   1.53   
0%
35.0%
BPMCBlueprint Medicines   1.35   
0%
31.0%
VTYXVentyx Biosciences   1.13   
0%
26.0%
NUVLNuvalent   0.48   
0%
11.0%
AKROAkero Therapeutics   0.22   
5.0%
0%
APLSApellis Pharmaceuticals   0.62   
14.0%
0%
CRNXCrinetics Pharmaceuticals   0.81   
18.0%
0%
MDGLMadrigal Pharmaceuticals   0.98   
22.0%
0%
ACLXArcellx   1.12   
26.0%
0%
ETNB89bio   1.64   
38.0%
0%
UTHRUnited Therapeutics   2.02   
47.0%
0%
REPLReplimune   2.29   
53.0%
0%
AMLXAmylyx Pharmaceuticals   3.48   
81.0%
0%

Complementary Tools for Ascendis Stock analysis

When running Ascendis Pharma's price analysis, check to measure Ascendis Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ascendis Pharma is operating at the current time. Most of Ascendis Pharma's value examination focuses on studying past and present price action to predict the probability of Ascendis Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ascendis Pharma's price. Additionally, you may evaluate how the addition of Ascendis Pharma to your portfolios can decrease your overall portfolio volatility.
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments
ETF Categories
List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences